Explore the latest news from Khondrion and its team.
December 4, 2015 - FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the...
Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound...
Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome NIJMEGEN – Khondrion, the Dutch pharmaceutical company focusing on small...
NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial...
Former Kinesis Director Clinical Development Edwin Spaans appointed as Khondrion's Chief Medical Officer. NIJMEGEN –December 15, 2014 ‐ Khondrion,...
Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of...
How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...
When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...
How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...
When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...
How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...
